Patents by Inventor James L. Trevaskis

James L. Trevaskis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160102126
    Abstract: The expression of a mRNA encoding a putative 76 amino acid, secreted protein (“Enho1”) was found to negatively correlate with fasting triglyceride and cholesterol levels. A recombinant adenovirus was used to increase the expression of Enho1 mRNA in two mouse models of obesity, KK-Ay and Lepob/Lepob mice. Over-expression of Enho1 by adenovirus injection significantly, and reproducibly, reduced fasting triglyceride and cholesterol levels in both models. In addition, transgenic mice strains were made that over express Enho1 protein. Additionally, the expression of a key gene involved in lipogenesis (fatty acid synthase) and FAS protein levels were reduced by ENHO1 adenoviral treatment in Lepob/Lepob mice.
    Type: Application
    Filed: October 26, 2015
    Publication date: April 14, 2016
    Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Andrew A. Butler, James L. Trevaskis
  • Publication number: 20140066370
    Abstract: The disclosure provides Polypeptide Conjugates with multiple improved pharmacological and pharmacokinetic properties and their use in treating various diseases and conditions, such as diabetes and/or obesity.
    Type: Application
    Filed: November 23, 2010
    Publication date: March 6, 2014
    Applicant: Amylin Pharmaceuticals, LLC
    Inventors: Behrouz Bruce Forood, Soumitra S. Ghosh, James L. Trevaskis, Chengzao Sun, Odile Esther Levy, Lawrence J. D'Souza, Christopher J. Soares
  • Publication number: 20130231280
    Abstract: The expression of a mRNA encoding a putative 76 amino acid, secreted protein (“Enho1”) was found to negatively correlate with fasting triglyceride and cholesterol levels. A recombinant adenovirus was used to increase the expression of Enho1 mRNA in two mouse models of obesity, KK-Ay and Lepob/Lepob mice. Over-expression of Enho1 by adenovirus injection significantly, and reproducibly, reduced fasting triglyceride and cholesterol levels in both models. In addition, transgenic mice strains were made that over express Enho1 protein. Additionally, the expression of a key gene involved in lipogenesis (fatty acid synthase) and FAS protein levels were reduced by ENHO1 adenoviral treatment in Lepob/Lepob mice.
    Type: Application
    Filed: March 26, 2013
    Publication date: September 5, 2013
    Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Andrew A. BUTLER, James L. TREVASKIS
  • Patent number: 8518892
    Abstract: The expression of a mRNA encoding a putative 76 amino acid, secreted protein (“Enho1”) was found to negatively correlate with fasting triglyceride and cholesterol levels. A recombinant adenovirus was used to increase the expression of Enho1 mRNA in two mouse models of obesity, KK-Ay and Lepob/Lepob mice. Over-expression of Enho1 by adenovirus injection significantly, and reproducibly, reduced fasting triglyceride and cholesterol levels in both models. In addition, transgenic mice strains were made that over express Enho1 protein. Additionally, the expression of a key gene involved in lipogenesis (fatty acid synthase) and FAS protein levels were reduced by ENHO1 adenoviral treatment in Lepob/Lepob mice.
    Type: Grant
    Filed: August 2, 2010
    Date of Patent: August 27, 2013
    Assignee: Board of Supervisors of Louisiana State University and Agricultural Mechanical College
    Inventors: Andrew A. Butler, James L. Trevaskis
  • Publication number: 20120071401
    Abstract: Provided herein are methods to treat estrogen deficiency in mammals by administering amylin agonist compounds. Also provided herein are methods to treat obesity and overweight in estrogen-deficient mammals; methods to reduce or maintain body weight and/or body fat in estrogen-deficient mammals; and methods to increase Bdnf levels in mammals by administering effective amounts of amylin agonist compounds. The estrogen deficiency may be caused by menopause, perimenopause, post-menopause, ovarian dysfunction, an overectomy, a hysterectomy, and the like. The amylin agonist compounds may be any known in the art or described herein, such as pramlintide, davalintide, or SEQ ID NO: 142.
    Type: Application
    Filed: April 9, 2010
    Publication date: March 22, 2012
    Applicant: Amylin Pharamaceuticals, Inc.
    Inventors: Jonathan David Roth, James L. Trevaskis, David G. Parkes
  • Publication number: 20100299769
    Abstract: The expression of a mRNA encoding a putative 76 amino acid, secreted protein (“Enho1”) was found to negatively correlate with fasting triglyceride and cholesterol levels. A recombinant adenovirus was used to increase the expression of Enho1 mRNA in two mouse models of obesity, KK-Ay and Lepob/Lepob mice. Over-expression of Enho1 by adenovirus injection significantly, and reproducibly, reduced fasting triglyceride and cholesterol levels in both models. In addition, transgenic mice strains were made that over express Enho1 protein. Additionally, the expression of a key gene involved in lipogenesis (fatty acid synthase) and FAS protein levels were reduced by ENHO1 adenoviral treatment in Lepob/Lepob mice.
    Type: Application
    Filed: August 2, 2010
    Publication date: November 25, 2010
    Inventors: Andrew A. Butler, James L. Trevaskis
  • Publication number: 20090253619
    Abstract: The expression of a mRNA encoding a putative 76 amino acid, secreted protein (“Enho1”) was found to negatively correlate with fasting triglyceride and cholesterol levels. A recombinant adenovirus was used to increase the expression of Enho1 mRNA in two mouse models of obesity, KK-Ay and Lepob/Lepob mice. Over-expression of Enho1 by adenovirus injection significantly, and reproducibly, reduced fasting triglyceride and cholesterol levels in both models. In addition, transgenic mice strains were made that over express Enho1 protein. Additionally, the expression of a key gene involved in lipogenesis (fatty acid synthase) and FAS protein levels were reduced by ENHO1 adenoviral treatment in Lepob/Lepob mice.
    Type: Application
    Filed: February 5, 2008
    Publication date: October 8, 2009
    Inventors: Andrew A. Butler, James L. Trevaskis